Moderna stock forfeits gains as first US bird flu death puts vaccine ...
1 day ago · Moderna’s revenue fell 64% to just below $7 billion in 2023 (far below the $18.5 billion in sales reported in 2020), and the company reported a loss of roughly $12 per share.
Moderna Is Gambling on China as Other U.S. Companies Pull Back
1 day ago · When Moderna reached a deal in 2023 to bring its medicines to China, the news got out before the biotechnology company said anything ...
Moderna Stock Soars After First US Bird-Flu Death - Investopedia
2 days ago · Moderna shares jumped more than 10% to lead S&P 500 gainers Tuesday, a day after the first bird-flu death was reported in the U.S. The biotech company is developing a vaccine for H5N1.
Moderna CEO confronts challenges for RSV, COVID businesses
3 days ago · Moderna’s stock price has dropped about 60% in the past 12 months. Facing this set of challenges, Moderna in September laid out a plan to cut annual R&D spending by more than 20%, or $1.1 ...
Moderna R&D day: $1 billion in cost cuts, 10 product launches
Sep 12, 2024 · Moderna on Thursday said it plans to cut around $1.1 billion in expenses by 2027 and win approvals for several new products as it charts a path forward after the rapid decline …
News Details - Moderna
Mar 26, 2024 · mRNA-1283 induced a more robust immune response compared to Spikevax® COVID-19 vaccine, mRNA-1273.222. Next-generation mRNA vaccine design offers the potential of longer shelf life and storage advantages, and paves the way for combination vaccine against influenza and COVID-19, mRNA-1083.
News Details - Moderna
Mar 27, 2024 · Announces next-generation COVID-19 vaccine candidate as fourth respiratory vaccine to successfully meet its Phase 3 endpoints. Expects two more Phase 3 readouts in 2024, including combination vaccine against flu and COVID-19, and vaccine against CMV.
News Details - Moderna
Jan 8, 2024 · CAMBRIDGE, MA / ACCESSWIRE / January 8, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced business updates and progress on the Company's pipeline of transformative mRNA medicines. Moderna enters 2024 with 45 therapeutic and vaccine programs, nine of which are in late-stage development.
News Details - Moderna
Jun 10, 2024 · CAMBRIDGE, MA / ACCESSWIRE / June 10, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced that its Phase 3 trial of mRNA-1083, an investigational combination vaccine against influenza and COVID-19, has met its primary endpoints, eliciting a higher immune response than the licensed comparator vaccines used in the trial.
News Details - Moderna
Sep 11, 2023 · Moderna's updated COVID-19 vaccine contains spike proteins for the XBB.1.5 sublineage of SARS-CoV-2 to help prevent COVID-19 in individuals 6 months of age and older. With the U.S. FDA's decision, Moderna will begin shipping doses to vaccination sites across the U.S., with updated vaccines expected to be available in the coming days.